Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6114456 | Autoimmunity Reviews | 2015 | 8 Pages |
Abstract
The treatment of patients with CSS must be tailored to individual patients according to the presence of poor prognostic factors. A combination of high-dose corticosteroids and cyclophosphamide is still the gold standard for the treatment of severe cases, but the use of biological agents such as rituximab or mepolizumab seems to be a promising therapeutic alternative.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Antonio Greco, Maria Ida Rizzo, Armando De Virgilio, Andrea Gallo, Massimo Fusconi, Giovanni Ruoppolo, Giancarlo Altissimi, Marco De Vincentiis,